Blood Cancer Journal

Papers
(The H4-Index of Blood Cancer Journal is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Disparities in time to treatment with oral antimyeloma medications283
Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells214
BCR::ABL1-positive acute lymphoblastic leukemia as a high-risk feature of central nervous system relapse after allogeneic hematopoietic cell transplantation209
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease129
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency121
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report97
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes94
Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL88
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine86
Genomic landscape of hyperleukocytic acute myeloid leukemia85
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma80
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management76
A multiparametric niche-like drug screening platform in acute myeloid leukemia74
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study74
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity71
Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study71
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib68
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma68
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study63
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT57
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study55
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort55
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma54
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor52
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients49
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia48
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes47
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M45
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid45
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma44
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier44
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma44
Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma42
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma42
Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia41
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome41
Genome profiling with targeted adaptive sampling long-read sequencing for pediatric leukemia40
Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significa40
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review40
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study40
Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies40
0.68396496772766